The excess release of mediators can cause clinical features such as pruritus, flushing, nausea, vomiting, diarrhoea, abdominal pain, vascular instability and anaphylaxis. Also, complications may arise when mast cells accumulate in the skin, gastrointestinal tract, bone marrow, liver, spleen, and lymph nodes. [2] The clinical features of systemic mastocytosis are caused by accumulation of clonal...

The development of a second haematological disease during the course of systemic mastocytosis is a well-known phenomenon. In most of the cases, they consist of myelodysplasia or myeloproliferative disorders. The association with lymphoproliferative disorders has also been described, but it is uncommon and the relationship is not well established. We report a patient diagnosed with systemic mast...

The excess release of mediators can cause clinical features such as pruritus, flushing, nausea, vomiting, diarrhoea, abdominal pain, vascular instability and anaphylaxis. Also, complications may arise when mast cells accumulate in the skin, gastrointestinal tract, bone marrow, liver, spleen, and lymph nodes. [2] The clinical features of systemic mastocytosis are caused by accumulation of clonal...

The excess release of mediators can cause clinical features such as pruritus, flushing, nausea, vomiting, diarrhoea, abdominal pain, vascular instability and anaphylaxis. Also, complications may arise when mast cells accumulate in the skin, gastrointestinal tract, bone marrow, liver, spleen, and lymph nodes. [2] The clinical features of systemic mastocytosis are caused by accumulation of clonal...

Background Kounis Syndrome manifests as unstable vasospastic or nonvasospastic angina and is caused by the release of inflammatory mediators following an allergic reaction. A variety of causes have been reported including antibiotics, general anesthetics, latex, insect stings, drug eluting stents, etc. To the best of our knowledge, Kounis syndrome in the setting of systemic mastocytosis has not...

Despite promising reports of the use of omalizumab as add-on therapy in patients with systemic mastocytosis and recurrent anaphylaxis during specific venom immunotherapy (VIT), unpredicted adverse effects may lead to therapy failure. We present the case of a patient with systemic mastocytosis and Hymenoptera venom allergy who was administered omalizumab as add-on therapy to improve VIT tolerabi...

Background. Mastocytosis is a disease characterized by the presence of mast cells in various organs. The skin affected most often. Almost every patient diagnosed with mastocytosis has lesions. This redness, itching, abdominal pain, diarrhea, musculoskeletal hypotension. These features result from release cell mediator and its infiltration into target Materials methods. article describes symptom...

BackgroundSystemic mastocytosis is a hematological disease in which aberrant mast cells accumulate because of gain-of-function mutations the KIT receptor. Group 2 innate lymphoid (ILC2s) are effector type immune responses that also express and colocalize with at barrier tissue sites. In mouse models, cell-ILC2 crosstalk can drive local inflammation. However, possible role for ILC2s pathophysiol...

Systemic Mastocytosis is a rare condition characterized by the abnormal proliferation of Mast Cells. Presentation as a solitary vertebral body lesion is extremely uncommon and may be confused with more ominous conditions such as metastasis. Familiarity with the condition can heighten clinical suspicion, direct tissue diagnosis, guide management and indicate appropriate follow up. We present a c...

Systemic mastocytosis occurred as a fatal event in a patient with long-standing polycythemia vera. The patient had been treated over the course of 21 yr with radioactive phosphorus. Possible relationships between mastocytosis and polycythemia vera, and also between mastocytosis and treatment with ionizing radiation, are discussed. Histopathologic and electron microscopic findings are illustrate...